Sold as Vibativ. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Telavancin (sold as Vibativ), first approved Jun 21, 2013, with 0 new uses approved and 0 published complete response letters.
| Vibativ | Part B | $994K | -7% | 123 |
| Vibativ | Part D | $522K | -6% | 34 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular DrainageSubarachnoid Hemorrhage, Aneurysmal · Aaron Cook | Phase 4 | Recruiting | Nov 7, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 21, 2013 | VibativNDA 22407 · New indication | Theravance Inc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA